US Stock MarketDetailed Quotes

NVO Novo-Nordisk A/S

Watchlist

122.710
-0.040-0.03%

Close Apr 19 16:00 ET

122.400
-0.310-0.25%

Post 17:23 ET

546.81BMarket Cap46.20P/E (TTM)

Novo-Nordisk A/S Stock Forum

Shaaaw

Apr 7 21:40

Top companies and drugs by sales in 2023 from Nature Reviews Drug Discovery.
$Eli Lilly and Co(LLY.US)$ and $Novo-Nordisk A/S(NVO.US)$ are not on the list (they will be next year of course...). Just shows how forward looking our industry is as both have higher market caps than any of the top 10 companies

Shaaaw

Apr 2 01:41

$Novo-Nordisk A/S(NVO.US)$ & $Eli Lilly and Co(LLY.US)$ 's MCap increased by $285 bil in Q1 2024 alone, driven mostly by growth of the GLP-1 franchises,
Revenue from both companies GLP-1 drugs totaled $33.6 bil last yr, an impressive number that almost certainly will grow this yr,
But let's put that $285 bil incr in mkt value into perspective,
$AbbVie(ABBV.US)$ has a $315 bil MCap, not much bigger than the combined Q1 incr in mkt value for LLY & NVO,
ABBV had $54 bil in revenue in 2023, compared ...

Best Q1 since 2019: Bubble or bliss?

Moomoo AI

Mar 27 16:08

The high price of Ozempic in the US compared to other countries has drawn criticism and calls for price reduction. This could potentially impact Novo Nordisk's revenue if the company is pressured to lower its prices.

Sen. Sanders Goes After Novo Nordisk on Study on Ozempic Low Manufacture Cost

Meltyy

Mar 26 22:30

Recent Biopharma Funding Activity

20 public and private funding events 👇
– Private Funding –
Clasp Therapeutics
🏦 Launched w/ $150M Series A financing from several investors to develop their T-cell engagers (TCE) pipeline.
Capstan Therapeutics
🏦 Closed $175M Series B financing led by RA Capital Management to support the advancement of CPTX2309, their in vivo CAR-T product candidate.
Engrail Therapeutics
🏦 Closed $157M Series B financing round to advance the development of their therapies.
Pan...

Moomoo AI

Mar 26 10:16

Viking Therapeutics is viewed as a long-term rival to Eli Lilly and Novo Nordisk in the weight-loss drug market. The rising share price makes it a costly acquisition prospect. The entry of competitors could potentially lower medicine costs, relieving the U.S. healthcare system's financial strain.

Viking Therapeutics Posts Promising Early Weight-Loss Data as Cost Worries Escalate -- Barrons.com

Meltyy

Mar 25 21:43

🔥 M&A News 🔥

$AbbVie(ABBV.US)$ to acquire $Landos Biopharma(LABP.US)$
⇒ $137.5M deal at $20.42/sh 💰💰
⇒ strengthens portfolio in inflammatory & autoimmune diseases
⇒ Adds lead asset NX-13 (Ph2 trial UC)
$Nuvation Bio(NUVB.US)$ to acquire AnHeart Therapeutics
⇒ all-stock transaction
⇒ transforms NUVB into late-stage global oncology company
⇒ Includes taletrectinib with ongoing trials NSCLC)
$Novo-Nordisk A/S(NVO.US)$ to acquire Cardior Pharmaceuticals
⇒ 1.025 B euros deal 💰💰
⇒ strengthens pi...

Moomoo AI

Mar 25 07:26

The acquisition of Cardior Pharmaceuticals is seen as a strategic move by Novo Nordisk to establish a presence in the cardiovascular disease market, leveraging Cardior's RNA-targeting therapies and its lead compound, CDR132L.

Novo Nordisk Boosts Cardiovascular Pipeline With $1.1 Bln Purchase of Cardior Pharmaceuticals

125?

$Novo-Nordisk A/S(NVO.US)$

ehttrader

Mar 21 02:05

NVO and LLY "blinked" at one point during the market.

$Novo-Nordisk A/S(NVO.US)$$Eli Lilly and Co(LLY.US)$
Covering obesity drugs would lead to higher COSTS for the U.S. than the anticipated SAVINGS, potentially RAISING the U.S. 🇺🇸 DEFICIT over the next 10 years.- CBO

No comment yet

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall